Analysis of Survival of Prostate Cancer Patients in Japan and the USA

  • Kyoichi Imai
  • Takanori Suzuki
  • Toshihiro Shimizu
  • Hidetoshi Yamanaka
  • Hiroshi Kanetake
  • Hideki Sakai
  • Yuzo Minami
  • Yutaka Saito
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 324)

Abstract

The prognosis of U.S.A. patients with prostate cancer based on reports from the American College of Surgeons and Roswell Park Cancer Institute was compared with that of Japanese in Nagasaki and Gunma. There was more than a 10% difference in survival rate between the two countries. Several clinical parameters were analyzed to determine the basis for this difference. In general, stage distribution, metastatic sites, bone pain and alkaline phosphatase in the USA patients with Stage D disease were more severe than in the Japanese patients. Moreover the prostate cancer death rate in the USA was higher than that in Japan. However, only the distribution of pathological grade in the USA was better than that in Japan. From these results, it is difficult to conclude that prostate cancer in the USA is more aggressive than in Japan. The possibility of selection bias in these studies is discussed.

Keywords

Adenocarcinoma Oncol Stratification Parkin Kato 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parkin D.M., Laara E. and Muir C.S., Estimates of the worldwide frequency of sixteen major cancers in 1980, Int. J. Cancer 41:184–197 (1988).PubMedCrossRefGoogle Scholar
  2. 2.
    Waterhouse J.A.H., Muir C.S., Shanmugaratnam K. and Powell J., Cancer incidence in five continents, IARC Sci. Pub., Vol. IV, 42 (1982).Google Scholar
  3. 3.
    Akazaki K. and Stemmermann G.N., Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii, J. Natl. Cancer Inst. 50:1137–1144 (1973)PubMedGoogle Scholar
  4. 4.
    Yatani R., Chigusa I., Akazaki K., Stemmermann G.N., et al, Geographic pathology of latent prostatic carcinoma, Int. J. Cancer 29:611–616 (1982).PubMedCrossRefGoogle Scholar
  5. 5.
    Murphy G.P., Saroff J., Joiner J. and Gaeta J., Prostatic carcinoma, NY State J. of Med. 75:1663–1669 (1975).Google Scholar
  6. 6.
    Slack N.H., Brady M.F. and Murphy G.P., Prostatic carcinoma, NY State J. of Med. 83:699–705 (1983).Google Scholar
  7. 7.
    Slack N.H., Lane W.W., Priore R.L. and Murphy G.P., Prostatic cancer, Urology 27(3):205–213 (1986).PubMedCrossRefGoogle Scholar
  8. 8.
    Murphy G.P., Natarajan N., Pontes J.E., Schmitz R.L., Smart C.R., Schmidt J.D. and Mettlin C., The national survey of prostate cancer in the United States by the American College of Surgeons, J. Urol. 127:928–934 (1982).PubMedGoogle Scholar
  9. 9.
    Mettlin C., Natarajan N. and Murphy G.P., Recent patterns of care of prostate cancer patients in the United States: Results from the surveys of the American College of Surgeons Commission on Cancer, Int. Advances in Surgical Oncol. 5:277–321 (1982).Google Scholar
  10. 10.
    Soloway M.S., Hardeman S.W., Hickey D., Raymond J., Todd B., Soloway S. and Moinuddin M., Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan, Cancer 61:195–202 (1988)PubMedCrossRefGoogle Scholar
  11. 11.
    Imai K., Suzuki T., Hayashi M., Nakazawa Y., Nakata S., Yamanaka H., Kitaura K., Tomaru Y., Miki M., Kato N., Sato J., Takahashi H., Koya A., Kurihara H., Makino T., Ebihara., Shinozaki T., Kurosawa I., Matsushita I. and Takeuchi H., Prognostic factor for prostate cancer, Jpn I. Urol. 81(8):1217–1224 (1990).Google Scholar
  12. 12.
    Imai K., Onuki T., Okabe K., Kurita M., Kurokawa K., Yamanaka H. and Tomaru Y., Prognostic factor for the patients with bone metastasis of prostate cancer, proceeding of the first workshop on prostate cancer 1990:54–57 (1990).Google Scholar
  13. 13.
    Imai K., Zinbo S., Shimizu K., Yamanaka H., Kumasaka F. and Sato Z., Clinical characteristics of prostatic cancer detected by mass screening, The Prostate 12:199–207 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    Kumamoto Y., Tsukamoto T., Umehara T., et al, Clinical studies endocrine therapy for prostatic carcinoma (2): Prognosis of patients with prostatic carcinoma given endocrine therapy, and analyses on causes of death and side effect of endocrine therapy, Ada. Urol. Jpn., 36:285–293 (1990).Google Scholar
  15. 15.
    The Veterans Administration Cooperative Urological Research: Treatment and survival of patients with cancer of prostate, Surg. Gynecol. Obstet. 124:1011–1017 (1969).Google Scholar
  16. 16.
    Eisenberger M.A., Chemotherapy for prostate carcinoma, NCI Monographs 7:151–163 (1988).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Kyoichi Imai
    • 1
  • Takanori Suzuki
    • 1
  • Toshihiro Shimizu
    • 1
  • Hidetoshi Yamanaka
    • 1
  • Hiroshi Kanetake
    • 2
  • Hideki Sakai
    • 2
  • Yuzo Minami
    • 2
  • Yutaka Saito
    • 2
  1. 1.Gunma University Oncology Study GroupSchool of Medicine, Gunma UniversityMaebashiJapan
  2. 2.Nagasaki Prostate Cancer Research Group, Nagasaki, JapanUniversity, School of MedicineNagasakiJapan

Personalised recommendations